Both of the S1P-catabolizing genes, SGPP1 and PLPP3, showed high predictive value for response to systematic therapy in invasive breast carcinoma patients and especially in the HER2+ and basal subtypes (Table 4). This evidence concerns the gene PLPP3 and invasive breast carcinoma.